Enhanced Group posts $62 million loss after costly Enhanced Games
The telehealth firm’s second-quarter results reveal that the Las Vegas sports event, which permitted performance-enhancing drugs, was a commercial failure, prompting a pivot to a lower-cost online series.
The Enhanced Group, a telehealth company backed by Peter Thiel, has reported a net loss of nearly $62 million for the second quarter. The financial setback is largely attributed to the costs of hosting the Enhanced Games, a Las Vegas sports competition that allowed athletes to use performance-enhancing drugs typically banned in professional sports.
The event, which has been described as the “steroid Olympics,” generated $17.7 million in revenue during the quarter. However, the majority of this income was derived from sponsorships tied to the games rather than the company’s core telehealth business. The report offers scant information regarding the financial performance of the underlying health treatment platform, which sells FDA-approved products such as peptides, testosterone injections, and GLP-1s for weight loss.
The Enhanced Group was founded in 2023 and underwent an initial public offering earlier this year at a valuation of $1.2 billion. Despite the high valuation, the recent earnings cast doubt on previous executive claims that the games would become an annual occurrence. The company now faces the challenge of either significantly increasing revenue or tolerating substantial annual losses to maintain the event.
In response to the financial strain, the company has launched a new online series called Enhanced Breakers. This initiative is designed to operate at a fraction of the cost of a full Games event while keeping athletes competing and sponsors engaged year-round. The shift signals a potential pivot away from the high-profile, high-cost physical competition.
The broader peptide industry continues to gain ground, aided by a recent decision from the US Food and Drug Administration to reclassify several substances that had previously existed in a legal grey area. Although an additional review process is required before the full impact is realised, the move highlights the government’s interest in deregulating the sector.
The FDA is overseen by the US Department of Health and Human Services, led by Robert F. Kennedy Jr., whose unconventional views on health have drawn criticism from various professionals. Despite this, Silicon Valley remains a hub for peptide startups, with companies such as Superpower and Noho Labs capitalising on the tech industry’s interest in biohacking and health supplements.
